Goldman Sachs Thinks Lilly (LLY) is Compelling With or Without Potential Blockbuster AD Drug Sola; Analyst Raises Rating to 'Buy'
Go back to Goldman Sachs Thinks Lilly (LLY) is Compelling With or Without Potential Blockbuster AD Drug Sola; Analyst Raises Rating to 'Buy'| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 732.20 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $732.20 | 52 Week High | $88.16 | |||
| Open | $732.20 | 52 Week Low | $67.88 | |||
| Day High | $732.20 | P/E | 169.49 | |||
| Day Low | $732.20 | EPS | $4.32 | |||
| Volume | 193 | |||||
